In Paxil Fraud Scheme, Glaxo Pays The Price

Law360, New York (March 29, 2006, 12:00 AM EST) -- GlaxoSmithKline PLC will fork over $14 million to U.S. states in order to settle allegations that the drug giant forced government health plans to pay inflated prices for its widely-used antidepressant Paxil in a fraudulent scheme to block generic versions of the drug from being made.

The suit and the settlement, filed yesterday in a Pennsylvania federal court, stemmed from charges that a series of baseless patent-infringement lawsuits brought by Glaxo against generic drug-makers was part of the company’s scheme to delay the introduction of cheaper...
To view the full article, register now.